ARS Pharmaceuticals: Still A Buy As Neffy Access Improves – Image for illustrative purposes only (Image credits: Pexels)
ARS Pharmaceuticals continues to advance its position in the allergy treatment market through steady improvements in insurance coverage and regulatory updates for its flagship product, neffy. The needle-free epinephrine nasal spray addresses a long-standing need for patients at risk of severe allergic reactions. Recent developments in formulary placements and label expansions have broadened availability, supporting renewed interest among investors evaluating the company’s growth trajectory.
Formulary Expansions Drive Broader Coverage
Major pharmacy benefit managers and health plans have added neffy to their national formularies in recent months. This includes placements with OptumRx, Cigna Healthcare, and Navitus Health Systems, which together have lifted overall commercial coverage above 90 percent. Patients now face fewer prior authorization hurdles in many plans, easing the path from prescription to access.
State Medicaid programs have also progressed, with nine states now offering unrestricted coverage. Additional states remain in active discussions, with expectations that a majority will follow suit by early 2027. These steps reduce out-of-pocket costs for a wider patient population and support higher prescription volumes over time.
FDA Label Change Removes Pediatric Age Limits
In late March 2026 the FDA approved removal of the minimum age requirement on the 1 mg dose of neffy. All patients weighing 33 pounds or more can now use the product without an age restriction, simplifying decisions for families of younger children. The update also reinforces recommendations for carrying the medication in its blister packaging or provided case.
Schools have responded positively, with more than 10,000 institutions enrolling in a no-cost emergency supply program. Each participating school receives two cartons of neffy for on-site use, further embedding the product in everyday settings where allergic reactions can occur.
Revenue Momentum and Cash Position
First-quarter 2026 results showed U.S. net product revenue from neffy reaching $17.5 million within total revenue of $22.7 million. Management highlighted growing new-patient starts alongside the beginning of prescription renewals, which are expected to accelerate in the second half of the year. The company ended the quarter with $201 million in cash and short-term investments, sufficient to reach cash-flow breakeven without additional financing.
International partnerships continue to contribute through collaboration and supply revenue, including milestone payments tied to European approvals. These diversified streams help offset ongoing commercial investments while the domestic business scales.
Analyst Sentiment Remains Constructive
Wall Street consensus rates the stock a Strong Buy, with an average price target near $25. This reflects confidence that expanded access and label flexibility will translate into sustained market-share gains against traditional injectable options. Some observers note that execution on remaining payor contracts and prescriber adoption will determine the pace of profitability.
Overall, the combination of regulatory progress, payer momentum, and a solid balance sheet positions ARS Pharmaceuticals to capitalize on rising demand for convenient epinephrine delivery. Continued focus on unrestricted coverage and patient awareness programs should support further upside as the product matures.
